MUMBAI, February 26, 2013 /PRNewswire/ --
CPhI conferences announces a meeting of experts in the pharmaceuticals industry speaking on an area of vital importance in developing high quality APIs, taking place from 16 - 17 April 2013 at Hilton International Airport, Mumbai India.
Dr. Allan S. Myerson, Professor of the Practice of Chemical Engineering, Massachusetts Institute of Technology (USA)
"Crystallization is a crucial purification step in the pharmaceutical, chemical and food industries. Control of purity, crystal size, crystal shape and polymorphism is a major factor in crystallization process development and downstream product development."
Dr. Myerson presents on continuous crystallization of pharmaceuticals which is one of his core area of expertise.
Dr. Robin Rogers, Robert Ramsay Chair of Chemistry, University of Alabama (USA) and Editor-in-Chief Crystal Growth & Design
"Understanding and controlling crystallization of an API can make or break a company, while finding new crystalline forms or crystallization processes can lead to new and exciting business opportunities."
Dr. Robin will be discussing issues around what happens when co-crystals don't crystallize.
Dr. Preetam Ghogale, Head Pre-formulations, Piramal Enterprises
"Crystallization pays! You just need to understand it better."
Dr. Preetam presents the role of solubility during crystallization by evaluating different solvent systems and combinations to achieve right crystallization.
Other experts include:
- Dr. Agam Sheth, Principal Scientist, Merck Research Laboratories (USA)
- Dr. Anant Paradkar, Director, Center for Pharmaceutical Engineering Science, University of Bradford (UK)
- Mr. Sethu Madhavan, Director Manufacturing, Teva API India and many more.
The Crystalization conference has been designed keeping the science for business perspective in mind. It addresses the most critical challenges of the pharmaceutical industry. There are discussions around techniques to achieve smooth scale up involving crystallization procedure. Furthermore, the important area of particle size, which is a key for developing APIs through crystallization, will be covered in depth. Crystallization is of vital importance for generics working on Polymorphs and hence there is a highlighted session on how crystallization can be effectively carried out to develop desired polymorphs.
This event has already generated interest in the industry with delegate registrations made by companies like Cipla, Ranbaxy Laboratories, Lupin, USV, Unimark Remedies, Shasun Pharmaceuticals, Alkem Laboratories, Aurobindo Pharma, Watson Pharma, Aarti Industries, Vardhman Chemtech, DSM Sinochem India, Srikrishna Pharma and so on.
Find out more about Crystallization 2013 conference on www.crystallization-india.com/pr
CPhI India is the largest and most important meeting place for the Indian pharma industry. Each year CPhI attracts around 850 exhibitors and 30,000 visitors to the show, providing us with an unrivalled reach to all the key decision makers in the Indian Pharma industry.
About UBM India
UBM India is a subsidiary of UBM plc, which is the second largest independent exhibition organiser in the world. It is the largest trade exhibition organiser in India, responsible for 26 exhibitions in different locations across the country. The company is also involved in the organisation of conference programmes throughout India and in the publications of trade journals and magazines. For further details please visit the UBM India website, http://www.ubmindia.in
Primary Media Contact: Shwetha Prabhu, firstname.lastname@example.org, 91-22-61727001
SOURCE UBM India Pvt. Ltd.